Antifungal Drug ADME Profiling Service

Antifungal ADME Profiling for Smarter Candidate Selection

Antifungal discovery programs often begin with encouraging in vitro potency, yet promising hits can stall when absorption, metabolic stability, plasma binding, or tissue distribution does not support meaningful exposure. For DMPK teams, the key question is not only whether a compound inhibits a fungal target, but whether the molecule can reach the relevant biological compartment with a workable exposure profile.

Creative Biolabs provides integrated antifungal drug ADME profiling service to help teams connect physicochemical behavior, permeability, metabolic risk, protein binding, metabolite formation, and early PK decisions into one practical development view.

Candidate Triage

Identify compounds limited by solubility, permeability, intrinsic clearance, transporter liability, or excessive binding before costly animal work.

DMPK Decision Support

Translate assay outputs into exposure hypotheses, species selection, dose-route considerations, and follow-on PK study recommendations.

Antifungal Context

Frame ADME findings around fungal pathogen biology, target-site exposure, potential combination therapy, and drug-drug interaction concerns.

Antifungal Drug ADME Profiling Service Details

Our service scope can be configured as a focused assay panel, a lead-candidate comparison, or an integrated in vitro ADME plus in vivo PK package for antifungal research programs.

In Vitro ADME Services

Physicochemical Properties

Aqueous Solubility: Measures compound solubility in relevant media, including physiological buffers, to anticipate oral absorption and formulation constraints.
LogP/LogD: Determines lipophilicity, a key predictor of membrane permeability, tissue distribution, and binding behavior.

Absorption and Permeability

Caco-2 Permeability: Uses human colon carcinoma cells to model intestinal permeability and predict oral absorption potential.
MDCK Permeability: Uses Madin-Darby canine kidney cells to assess permeability and potential active transport.
P-gp and Transporter Assays: Evaluates whether a drug is a substrate or inhibitor of key efflux transporters that may affect bioavailability and tissue penetration.

Metabolism and Stability

Microsomal Stability: Assesses metabolic stability and intrinsic clearance using liver microsomes from species such as human, rat, and mouse.
Hepatocyte Stability: Uses intact hepatocytes to evaluate metabolism and metabolite formation in a more physiologically relevant system.
CYP Inhibition and Induction: Assesses potential drug-drug interaction risk across major CYP enzymes, including CYP3A4, CYP2D6, and CYP2C9.
Metabolite Identification and Profiling: Uses high-resolution mass spectrometry to identify and quantify drug metabolites.

In Vivo Pharmacokinetics Services

Single-Dose PK

Administers a single dose in an animal model, such as mouse or rat, to determine Cmax, Tmax, AUC, half-life, clearance, and exposure behavior.

Multiple-Dose PK

Evaluates drug accumulation, exposure reproducibility, and steady-state concentration after repeated dosing.

Tissue Distribution

Measures drug concentration in tissues such as liver, kidney, brain, lung, skin, or other project-relevant sites to assess distribution and accumulation.

Bioavailability Studies

Compares exposure after oral and intravenous administration to calculate oral bioavailability and guide route selection.

PK/PD Study Integration

Links drug concentration profiles with antimicrobial effect against the fungal pathogen in vivo, supporting exposure-response interpretation and downstream modeling.

Sample Information

Required Amount

Sample amount varies by assay. Typically, milligram quantities are required for in vitro studies, while tens to hundreds of milligrams may be needed for in vivo PK studies.

Purity

Compounds should generally be at least 95% pure. Available structure, salt form, solubility notes, storage conditions, and stability information help accelerate study setup.

Deliverables

Raw data files from analytical instruments.
Formatted data tables and graphs.
A detailed final report covering experimental methods, results, data interpretation, and expert recommendations.
A results presentation and consultation with our scientific team.

Turnaround Time

Turnaround times are project-specific and depend on assay scope, analytical method readiness, animal model design, sample availability, and reporting requirements.

In Vitro Assays

Typically range from 3 to 6 weeks.

In Vivo PK Studies

Can range from 6 to 10 weeks, depending on study design and animal model.

Antifungal ADME Profiling Workflow for DMPK Decision-Making

Our workflow keeps the process straightforward and decision-oriented, moving from project goals and compound transfer to ADME assay execution and a comprehensive final report.

01

Project Consultation

We begin with a focused discussion of the compound background, antifungal program stage, intended route, assay priorities, and exposure-related concerns.

Key Input

Specific goals

02

Sample Submission

Your team submits the test compounds with available purity, structure, solubility, storage, and handling information needed for assay setup.

Key Input

Test compounds

03

Study Execution

Selected ADME assays are performed according to the agreed study plan, with appropriate analytical methods and quality checks.

Core Activity

ADME assays

04

Data Analysis & Reporting

Results are organized into interpretable tables, graphs, and scientific recommendations for compound triage and next-step PK planning.

Final Output

A comprehensive report

Antifungal ADME Data Package Deliverables

Each package is designed to help discovery, DMPK, pharmacology, and leadership teams understand what the compound can do, where the risks sit, and what should be tested next.

Package Element	Core Content	Decision Value
Physicochemical and Permeability Summary	Aqueous solubility, LogP/LogD, Caco-2, MDCK, and transporter findings.	Clarifies oral absorption limitations and whether formulation or route strategy needs adjustment.
Metabolic Stability and Clearance View	Microsomal stability, hepatocyte stability, intrinsic clearance, and species comparison.	Helps prioritize candidates with stronger exposure potential and useful translational relevance.
Protein Binding and Metabolite Profile	Plasma protein binding, unbound fraction, metabolite identification, and metabolite abundance trends.	Supports interpretation of active exposure, tissue availability, and follow-on bioanalysis priorities.
CYP and Interaction Risk Assessment	CYP inhibition or induction findings across major enzymes and related DDI considerations.	Flags interaction liabilities that matter for antifungal programs, especially where combination therapy may be relevant.
PK Recommendation Memo	Recommended dose route, species, sampling design, tissue readouts, and PK/PD or efficacy follow-up options.	Turns ADME results into an actionable development plan rather than disconnected assay outputs.

Published Data Highlights ADME Risk in Antifungal Lead Selection

Recent research on antifungal pyrazole derivatives showed that compounds with promising fungal-target activity still required ADMET interpretation, including physicochemical properties, solubility, predicted absorption, CYP interaction potential, and protein binding. The published data reinforce a core development lesson: antifungal potency should be interpreted together with exposure-enabling properties before a compound is advanced.

The figure shows oral bioavailability-related profiling for selected antifungal pyrazole substances, supporting the value of early ADME screening in lead prioritization. Creative Biolabs helps antifungal teams build this evidence experimentally through solubility, permeability, metabolic stability, protein binding, metabolite, enzyme interaction, and in vivo PK services.

Fig.1 Graph of oral bioavailability for pyrazole substances. ^1,2

Our Advantages in Antifungal ADME Profiling

Creative Biolabs combines mycology insight, DMPK execution, and integrated antifungal development support so ADME findings can guide real project decisions.

Antifungal ADME profiling service advantages. (Creative Biolabs Authorized)

Mycology Expertise

We understand fungal biology and the exposure challenges that can affect antifungal drug development.

Integrated Solutions

ADME services can connect with antifungal susceptibility testing, in vitro and in vivo efficacy models, and medicinal chemistry support.

State-of-the-Art Technology

Advanced LC-MS/MS and HRMS platforms support sensitive bioanalysis, metabolite work, and exposure measurement.

Speed and Quality

Streamlined workflows help deliver timely data while protecting analytical rigor and data integrity.

Customizable Service

We support flexible study designs, from single-assay screens to integrated packages that inform PK, PK/PD, efficacy, and safety planning.

Advance Antifungal Leads with Clear ADME Evidence

Share your compound set, activity data, and exposure questions. Our team can help define the fastest ADME and PK path for candidate triage.

Recommended Services for Antifungal Drug Research

After ADME profiling, many teams continue into PK, exposure-response modeling, safety assessment, or in vivo efficacy evaluation to decide whether a compound is ready for the next development gate.

Frequently Asked Questions

Early ADME profiling helps identify compounds with poor oral absorption, rapid metabolism, excessive protein binding, transporter liability, or drug-drug interaction risk before significant resources are invested in in vivo efficacy and safety studies.

Yes. We can evaluate solubility first, recommend assay-compatible handling conditions, and help interpret whether low solubility is a manageable formulation issue or a core developability limitation.

Many early ADME screens are fit-for-purpose discovery studies. When a project requires GLP-compliant or GLP-aligned work, we can discuss the required scope, documentation level, and study design during project planning.

We assess CYP inhibition or induction, transporter involvement, metabolite formation, and protein binding context. These data help determine whether a compound may need deeper DDI evaluation before combination or advanced PK work.

Yes. ADME and PK results can guide route, dose, sampling time points, tissue exposure questions, and whether PK/PD modeling should be added before or after an efficacy experiment.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video

References

Abd-Elhalim, Basma T., et al. "Antifungal activity and biocompatibility assessment with molecular docking and dynamic simulations of new pyrazole derivatives." BMC Biotechnology 25.1 (2025): 15. https://doi.org/10.1186/s12896-025-00948-8
Distributed under Open Access license CC BY 4.0, without modification.